NRF2 Gene Mutation
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (NCT04265534) | Calithera Biosciences, Inc | 2020-07-24 |
Track NRF2 Gene Mutation automatically
Every clearance here is in the API, with alerts when new ones post.